Skip to Content
Morningstar
Get 14 Days Free

Centene Corp CNC

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Centene Maintains Cautious Earnings Outlook for 2021; Shares Still Undervalued

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Centene turned in solid fourth-quarter results, in our opinion, and management maintained its adjusted EPS guidance for 2021 that was given at its December investor day. We do not anticipate changing our $85 fair value estimate based on these results and near-term guidance. In the long run, we believe Centene's prospects serving individuals in government-sponsored health insurance programs remain strong, which helps support our narrow moat view for the company.

Read Full Analysis

Company Profile

Business Description

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. After acquiring WellCare in early 2020, Centene serves nearly 25 million members, mostly in Medicaid (13 million), Medicare (5 million total, including 4 million in Part D plans and 1 million in Medicare Advantage), the individual exchanges (2 million), and other plans (4 million), including Tricare (West region), correctional facility, and international plans.

Contact
7700 Forsyth Boulevard, Centene Plaza
St. Louis, MO, 63105
T +1 314 725-4477
Sector Healthcare
Industry Healthcare Plans
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Aggressive Growth
Employees 71,300

Related

Stock Strategist Industry Reports
What a Democratic Sweep Means for Healthcare
We think the insurers could be most influenced by potential reforms.
Julie Utterback
Stock Strategist Industry Reports
Election Impact on U.S. Healthcare Looks Modest
Our moat ratings and undervalued view of the MCO and drug/biotech sectors are intact.
Julie Utterback
Commentary
Key ESG Issues Up for Shareholder Vote
Employee welfare and political influence are among the big environmental, social, and governance issues this year.
Jackie Cook
Our Picks
10 Undervalued Stocks With Momentum
These quality stocks have gained more than 15% in the last three months yet still look undervalued to us.
Susan Dziubinski
Stock Strategist Industry Reports
Investing With Our 2020 Healthcare Policy Outlook
We see risks for managed care but also opportunities to own moatworthy companies at sizable discounts.
Jake Strole
Credit Insights
New Issue Corporate Bond Market Reaches a Frenzied Pace
The draw of low interest rates combined with tight credit spreads keeps issuers coming back to the market for more.
David Sekera
Quarter-End Insights
Our Outlook for Health-Care Stocks
With macro-conditions improving, the focus should return to fundamentals in health care.
Alex Morozov
US Videos
Did Health-Care Reform Die in Massachusetts?
Health-care analyst Matt Coffina thinks the odds for health-care reform passing are around 50%, but that either way the impact on industry will be muted.
Pat Dorsey